Investing in emerging healthcare companies since 1998
Three funds totalling $500 million under management
Focus on Venture Capital & Growth Equity investments
Investment team of seven people located in London and Boston
Read more about MVM
27th February 2012
European Commission approves Esmya® for the pre-operative treatment of uterine fibroids
Gedeon Richter Plc. has announced that the European Commission has granted marketing authorisation to Esmya® 5mg tablet as pre- operative treatment of moderate to severe symptoms of uterine fibroids.
Read this article
European Commission approves Esmya® for the pre-operative treatment of uterine fibroids
Gedeon Richter Plc. has announced that the European Commission has granted marketing authorisation to Esmya® 5mg tablet as pre- operative treatment of moderate to severe symptoms of uterine fibroids.
Read this article
16th December 2011
Richter Announces EMA Approval for PregLem's Esmya
Gedeon Richter Plc. announces that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for Esmya® as pre-operative treatment of moderate to severe symptoms of uterine fibroids.
Read this article
Richter Announces EMA Approval for PregLem's Esmya
Gedeon Richter Plc. announces that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for Esmya® as pre-operative treatment of moderate to severe symptoms of uterine fibroids.
Read this article
13th December 2011
Tarsa Therapeutics Targets 2012 NDA Submission for its Ostora
Tarsa Therapeutics has confirmed that it is planning to submit a New Drug Application to the Food and Drug Administration in the second half of 2012 for OSTORA™, the company’s oral recombinant salmon calcitonin tablet for the treatment of postmenopausal osteoporosis.
Read this article
Tarsa Therapeutics Targets 2012 NDA Submission for its Ostora
Tarsa Therapeutics has confirmed that it is planning to submit a New Drug Application to the Food and Drug Administration in the second half of 2012 for OSTORA™, the company’s oral recombinant salmon calcitonin tablet for the treatment of postmenopausal osteoporosis.
Read this article
22nd November 2011
Health Information Announces Investment from MVM Life Science Partners
Health Information, the dominant provider of point of dispensing messaging in the UK, announces that it has secured a first round of funding from MVM Life Sciences LLP.
Read this article
Health Information Announces Investment from MVM Life Science Partners
Health Information, the dominant provider of point of dispensing messaging in the UK, announces that it has secured a first round of funding from MVM Life Sciences LLP.
Read this article
15th September 2011
Horizon Discovery Announces £11.3 Million Fundraising
Horizon Discovery, a leading provider of research tools to support the development of personalised medicines, has announced that it has completed a second closing of its Series C funding round, realising a cumulative total of £11.3m, with MVM Life Sciences LLP leading the second closing.
Read this article
Horizon Discovery Announces £11.3 Million Fundraising
Horizon Discovery, a leading provider of research tools to support the development of personalised medicines, has announced that it has completed a second closing of its Series C funding round, realising a cumulative total of £11.3m, with MVM Life Sciences LLP leading the second closing.
Read this article
